MedPath

NSI-189

Generic Name
NSI-189
Drug Type
Small Molecule
Chemical Formula
C22H30N4O
CAS Number
1270138-40-3
Unique Ingredient Identifier
YVE9U408ZL
Background

NSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).

Clinical Trials
Related News

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

Conditions
Major Depressive Disorder
Interventions
First Posted Date
2016-03-31
Last Posted Date
2016-09-21
Lead Sponsor
Neuralstem Inc.
Target Recruit Count
220
Registration Number
NCT02724735

Study of NSI-189 for Major Depressive Disorder

Phase 2
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2016-03-01
Last Posted Date
2017-02-24
Lead Sponsor
Neuralstem Inc.
Target Recruit Count
220
Registration Number
NCT02695472
Locations
🇺🇸

Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States

🇺🇸

Collaborative Neuroscience Network, LLC, Garden Grove, California, United States

🇺🇸

St. Louis Clinical Trials, LC, St. Louis, Missouri, United States

and more 9 locations

Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects

Phase 1
Completed
Conditions
Depression
Interventions
First Posted Date
2012-01-30
Last Posted Date
2014-04-02
Lead Sponsor
Neuralstem Inc.
Target Recruit Count
26
Registration Number
NCT01520649
Locations
🇺🇸

California Clinical Trials, Glendale, California, United States

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

Phase 1
Completed
Conditions
Depression
Interventions
First Posted Date
2011-03-09
Last Posted Date
2011-11-21
Lead Sponsor
Neuralstem Inc.
Target Recruit Count
35
Registration Number
NCT01310881
Locations
🇺🇸

California Clinical Trials, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy